|Description||SAR-629 is a Monoglyceride lipase (MGL) inhibitor and can also be known as 2-arachidonoylglycerol (2-AG) degradation inhibitor. MGL is a serine hydrolase which can hydrolyse 2-AG into arachidonic acid and glycerol. 2-AG is an endogenous ligand of cannabinoid receptors and it plays an important role in various physiological processes in the brain.|
|Solubility||Soluble in DMSO|
|Quality Standard||In-house standard|
|Shelf Life||2 month in rt, long time|
SAR-629 is a Monoglyceride lipase (MGL) inhibitor and can also be known as 2-arachidonoylglycerol (2-AG) degradation inhibitor. MGL is a serine hydrolase which ...
Endocannabinoids such as 2-arachidonoyl glycerol (2-AG) and arachidonoyl ethanolamide are biologically active lipids that are involved in a number of synaptic p...
KML-29, a effective MAGL inhibitor, has been found to have probable effect against neuropathic pain. IC50: 15, 43, and 5.9 nM (mouse, rat, and human brain prote...
JJKK 048, a benzodioxol derivative, has been found to a MAGL inhibitor that could probably be significant in anticancer and anti-inflammatory studies. IC50: 0.4...
URB602, a cell-permeable N-biphenyl carbamate compound, is a selective inhibitor of monoglycerol lipase (MGL). The IC50 = 28 μM and Km = 20 μM. It does not inhi...
JZP 361 is a reversible, potent and selective inhibitor of human recombinant MAGL (hMAGL) with IC50 value of 46 nM. It shows affinity for H1 receptors but shows...
JZL 184 is the first selective inhibitor of monoacylglycerol lipase (MAGL) with IC50 of 8 nM.
NF 1819 is a selective irreversible β-lactam-based monoacylglycerol lipase inhibitor with IC50 values of 0.25 and 7.4 nM at rMAGL and hMAGL.